MEGIN, is the global leader for Magnetoencephalography (MEG) technology, a non-invasive, functional brain mapping solution for the diagnostic workup, treatment strategy and intervention of neurological conditions. Through innovation and passionate exploration of the endless possibilities, specialists from close to one hundred sites from around the world have used our MEG technology to study pathological and eloquent areas of the brain in patients diagnosed with neurological disorders such as epilepsy, brain tumors, autism, Alzheimer’s and vascular malformations. MEGIN’s global presence has revolutionized the ability to detect magnetic fields generated in the brain as information travels through a highly complex neural network. With this information physicians may be able to provide minimally invasive treatment options that can lead to improved outcomes for a better quality of life and minimize the potential for neurological deficits.